GlassScriptPhysician profile
Said Ashraf
NPI 1649699034
$19,305.16
in general payments reported to CMS, 2019-2025
39 companies · $9,910 in 2025
The $9,910 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,580 · 2020: $1,520 · 2021: $855 · 2022: $640 · 2023: $1,319 · 2024: $3,482 · 2025: $9,910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,548 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,500 · Travel and Lodging: $3,412 · Consulting Fee: $2,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,548.49 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,500.00 |
| Travel and Lodging | $3,411.80 |
| Consulting Fee | $2,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,535.17 | 2022-2025 | Dragonfly Opstar, Diamondback Coronary, Navitor |
| Medtronic, INC. | $3,246.06 | 2022-2025 | Corevalve Evolut R, Symplicity G3, Linq II |
| Abiomed | $1,728.45 | 2019-2025 | Impella |
| Boston Scientific Corporation | $1,706.33 | 2019-2025 | Avvigo Guidance System, Enroute Transcarotid Stent, Rotapro |
| Penumbra, INC. | $1,528.73 | 2024 | Indigo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $805.57 | 2019-2025 | Lifevest |
| Shockwave Medical, INC | $613.69 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Inari Medical, INC. | $509.37 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Pharmaceuticals, INC | $370.82 | 2019-2024 | Xarelto |
| Terumo Medical Corporation | $339.20 | 2020-2021 | |
| Pfizer INC. | $256.70 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $206.70 | 2019-2023 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $199.68 | 2021-2023 | Farxiga, Brilinta, Wainua |
| Cardiovascular Systems INC. | $179.31 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $142.40 | 2019-2024 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $138.32 | 2019-2024 | Alphavac |
| Teleflex LLC | $123.87 | 2019 | |
| Impulse Dynamics (USA) INC. | $117.56 | 2023 | Optimizer |
| Merck Sharp & Dohme LLC | $84.33 | 2022-2023 | Verquvo |
| Scpharmaceuticals INC. | $61.53 | 2024-2025 | |
| Heartflow, INC. | $43.69 | 2023-2025 | Ffrct |
| Philips North America LLC | $42.76 | 2022-2025 | (5044) Mcot, Extended Holter |
| Asahi Intecc USA, INC. | $36.45 | 2025 | Asahi Coronary Wires |
| Altathera Pharmaceuticals LLC | $27.46 | 2023-2024 | Sotalol Hydrochloride |
| Bracco Diagnostics INC. | $22.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.54 | 2019 | |
| Cardiva Medical, INC. | $20.50 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Kiniksa Pharmaceuticals International, Plc | $20.09 | 2024 | Arcalyst |
| Stryker Corporation | $19.15 | 2025 | Flowtriever |
| Novo Nordisk INC | $18.72 | 2025 | Wegovy |
| Chiesi USA, INC. | $18.17 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $17.66 | 2020 | |
| Bridgebio Pharma, INC. | $17.63 | 2025 | Attruby |
| Insulet Corporation | $17.58 | 2019 | |
| W. L. Gore & Associates, INC. | $16.00 | 2023 | Gore Cardioform Septal Occluder |
| Mannkind Corporation | $15.17 | 2025 | |
| Daiichi Sankyo INC. | $13.88 | 2023 | Injectafer |
| Amgen INC. | $12.12 | 2019 | |
| Preventice Services, LLC | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Said Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.